CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 3
Recruiting
NCT05624749

Ianalumab

Sponsored by Novartis ↗
View on ClinicalTrials.gov ↗
Timeline
Study Dates
Start Date
March 2023
Est. Completion
December 2027
Enrollment Target
450 participants
Status
Recruiting
Study Design
Primary Endpoint
SRI-4 response rate at Week 52 with ianalumab versus placebo on background standard of care
Registry
ClinicalTrials.gov Record
Registry ID
NCT05624749
Direct Link
clinicaltrials.gov/NCT05624749 ↗
Related Treatment
Treatment Being Studied
Ianalumab →